OXiGENE (MATN) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of OXiGENE (OTCMKTS:MATN) from a hold rating to a buy rating in a research note published on Saturday morning. They currently have $0.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Mateon Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents for the treatment of cancer. Its product pipeline consists of VDAs-CA4P and OXi4503, which are in preclinical trail stage. Mateon Therapeutics, Inc., formerly known as OXiGENE, Inc., is based in SOUTH SAN FRANCISCO, United States. “
Separately, HC Wainwright set a $1.00 price target on OXiGENE and gave the company a buy rating in a research report on Wednesday.
OXiGENE (OTCMKTS:MATN) last issued its quarterly earnings results on Monday, April 16th. The biopharmaceutical company reported ($0.09) EPS for the quarter. sell-side analysts predict that OXiGENE will post -0.18 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “OXiGENE (MATN) Upgraded by Zacks Investment Research to Buy” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/04/22/oxigene-matn-upgraded-by-zacks-investment-research-to-buy.html.
Mateon Therapeutics, Inc, a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OXiGENE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OXiGENE and related companies with MarketBeat.com's FREE daily email newsletter.